SuspensionMRP Under Process
Official PMBI MRP is being updated for catalog code 2294.
Locate Jan Aushadhi KendraClinical Overview
Brimonidine Tartrate (0.1%, 0.2% w/v, alone or with Timolol/Brinzolamide) is a highly selective alpha-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. It exerts a dual mechanism: reducing aqueous humor production via alpha-2-mediated adenylyl cyclase inhibition in ciliary epithelium, and stimulating uveoscleral aqueous humor outflow via prostaglandin release. Also demonstrates retinal ganglion cell neuroprotective properties. Indicated for lowering intraocular pressure in open-angle glaucoma and ocular hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Instill one drop into the affected eye(s) twice or thrice daily, approximately 8 hours apart. Perform nasolacrimal occlusion for 1-2 minutes after instillation.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Ocular hyperemia, allergic conjunctivitis (foreign body sensation, follicular conjunctivitis), burning, stinging, dry mouth, drowsiness, fatigue, headache. Rare/Severe: Severe bradycardia, hypotension, syncope, and systemic CNS depression.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in neonates and infants under 2 years of age due to life-threatening central nervous system depression, apnea, and severe bradycardia. Contraindicated with monoamine oxidase (MAO) inhibitors. High incidence of delayed ocular allergic contact blepharoconjunctivitis.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Brimonidine Tartrate 0.2%w/v + Timolol Maleate 0.5%w/v Ophthalmic Solution
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Brimonidine Tartrate Eye drops 0.1% w/v
Brimonidine Tartrate (0.1%, 0.2% w/v, alone or with Timolol/Brinzolamide) is a highly selective alpha-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. It exerts a dual mechanism: reducing aqueous humor production via alpha-2-mediated adenylyl cyclase inhibition in ciliary epithelium, and stimulating uveoscleral aqueous humor outflow via prostaglandin release. Also demonstrates retinal ganglion cell neuroprotective properties. Indicated for lowering intraocular pressure in open-angle glaucoma and ocular hypertension.
Brinzolamide Ophthalmic Suspension 1% w/v
Topical Carbonic Anhydrase Inhibitor (Dorzolamide 2% or Brinzolamide 1% suspension, alone or with Timolol) on the WHO Model List of Essential Medicines. It inhibits carbonic anhydrase II (CA-II) in the ciliary processes, slowing bicarbonate ion formation and reducing active sodium and fluid transport, thereby diminishing aqueous humor secretion by up to 20-30%. Indicated for intraocular pressure reduction in open-angle glaucoma and ocular hypertension.